Migdal Insurance & Financial Holdings Ltd. lowered its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.9% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 665,035 shares of the company’s stock after selling 65,000 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Merck & Co., Inc. were worth $97,201,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Rasp Wealth Solutions LLC increased its stake in shares of Merck & Co., Inc. by 6.2% in the third quarter. Rasp Wealth Solutions LLC now owns 5,584 shares of the company’s stock worth $811,000 after buying an additional 325 shares during the period. MSH Capital Advisors LLC raised its holdings in Merck & Co., Inc. by 2.1% during the 3rd quarter. MSH Capital Advisors LLC now owns 10,204 shares of the company’s stock valued at $1,482,000 after buying an additional 206 shares during the last quarter. Cornerstone Advisory LLC boosted its position in Merck & Co., Inc. by 15.7% during the 3rd quarter. Cornerstone Advisory LLC now owns 12,638 shares of the company’s stock valued at $1,836,000 after buying an additional 1,715 shares during the period. Ibex Wealth Advisors boosted its position in Merck & Co., Inc. by 59.7% during the 3rd quarter. Ibex Wealth Advisors now owns 165,708 shares of the company’s stock valued at $24,079,000 after buying an additional 61,957 shares during the period. Finally, Wellington Grp LLC boosted its position in Merck & Co., Inc. by 0.5% during the 3rd quarter. Wellington Grp LLC now owns 26,387 shares of the company’s stock valued at $3,834,000 after buying an additional 124 shares during the period. Institutional investors own 76.07% of the company’s stock.
Key Stories Impacting Merck & Co., Inc.
Investors following MRK have been watching these stories:
- Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
- Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
- Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on MRK shares. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Freedom Broker upped their price objective on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the company a “hold” rating in a research note on Monday, November 2nd. Argus started coverage on shares of Merck & Co., Inc. in a report on Tuesday, November 3rd. They set a “strong-buy” rating for the company. Weiss Ratings upgraded shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Finally, Barclays raised their target price on Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a research note on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $155.74.
Merck & Co., Inc. Stock Up 0.5%
Shares of MRK traded up $0.79 on Friday, reaching $147.74. The stock had a trading volume of 6,504,320 shares, compared to its average volume of 9,885,298. The firm has a market capitalization of $364.21 billion, a price-to-earnings ratio of 152.31, a price-to-earnings-growth ratio of 6.74 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. The company has a 50-day simple moving average of $146.16 and a 200-day simple moving average of $128.61. Merck & Co., Inc. has a 12-month low of $91.49 and a 12-month high of $156.92.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.40. The company had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.58 earnings per share. Sell-side analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current year.
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
